• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于自噬基因面板的骨髓增生异常综合征预后模型

Autophagy Gene Panel-Based Prognostic Model in Myelodysplastic Syndrome.

作者信息

Wang Ming-Jing, Liu Wei-Yi, Wang Xue-Ying, Li Yu-Meng, Xiao Hai-Yan, Quan Ri-Cheng, Huang Gang, Hu Xiao-Mei

机构信息

Department of Hematology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.

Graduate School, China Academy of Chinese Medical Sciences, Beijing, China.

出版信息

Front Oncol. 2021 Feb 5;10:606928. doi: 10.3389/fonc.2020.606928. eCollection 2020.

DOI:10.3389/fonc.2020.606928
PMID:33614490
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7894207/
Abstract

Abnormal autophagy is related to the pathogenesis and clinical symptoms of myelodysplastic syndrome (MDS). However, the effect of autophagy-related genes (ARGs) on the prognosis of MDS remains unclear. Here, we examined the expression profile of 108 patients with MDS from the GSE58831 dataset, and identified 22 genes that were significantly associated with overall survival. Among them, seven ARGs were screened and APIs were calculated for all samples based on the expression of the seven ARGs, and then, MDS patients were categorized into high- and low-risk groups based on the median APIs. The overall survival of patients with high-risk scores based on these seven ARGs was shorter than patients with low-risk scores in both the training cohort (P = 2.851e-06) and the validation cohort (P = 9.265e-03). Additionally, API showed an independent prognostic indicator for survival in the training samples [hazard ratio (HR) = 1.322, 95% confidence interval (CI): 1.158-1.51; P < 0.001] and the validation cohort (HR = 1.05, 95% CI: 1-1.1; P < 0.01). The area under the receiver operating characteristic curve (AUROC) of API and IPSS were 43.0137 and 66.0274 in the training cohorts and the AUC of the validation cohorts were 41.5361 and 72.0219. Our data indicate these seven ARGs can predict prognosis in patients with MDS and could guide individualized treatment.

摘要

异常自噬与骨髓增生异常综合征(MDS)的发病机制及临床症状相关。然而,自噬相关基因(ARGs)对MDS预后的影响仍不明确。在此,我们检查了来自GSE58831数据集的108例MDS患者的表达谱,并鉴定出22个与总生存期显著相关的基因。其中,筛选出7个ARGs,并根据这7个ARGs的表达计算所有样本的自噬预后指数(APIs),然后,根据APIs中位数将MDS患者分为高风险组和低风险组。在训练队列(P = 2.851e - 06)和验证队列(P = 9.265e - 03)中,基于这7个ARGs的高风险评分患者的总生存期均短于低风险评分患者。此外,在训练样本[风险比(HR)= 1.322,95%置信区间(CI):1.158 - 1.51;P < 0.001]和验证队列(HR = 1.05,95% CI:1 - 1.1;P < 0.01)中,APIs显示为生存的独立预后指标。在训练队列中,APIs和国际预后评分系统(IPSS)的受试者工作特征曲线下面积(AUROC)分别为43.0137和66.0274,在验证队列中,AUROC分别为41.5361和72.0219。我们的数据表明,这7个ARGs可预测MDS患者的预后,并可指导个体化治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8774/7894207/9fbb571d7a44/fonc-10-606928-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8774/7894207/5bfc0aae58a0/fonc-10-606928-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8774/7894207/e2c09067f9f1/fonc-10-606928-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8774/7894207/6c681f8a4d31/fonc-10-606928-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8774/7894207/5f3923408638/fonc-10-606928-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8774/7894207/bce3d7117cc7/fonc-10-606928-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8774/7894207/2a34c7e97379/fonc-10-606928-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8774/7894207/9fbb571d7a44/fonc-10-606928-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8774/7894207/5bfc0aae58a0/fonc-10-606928-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8774/7894207/e2c09067f9f1/fonc-10-606928-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8774/7894207/6c681f8a4d31/fonc-10-606928-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8774/7894207/5f3923408638/fonc-10-606928-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8774/7894207/bce3d7117cc7/fonc-10-606928-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8774/7894207/2a34c7e97379/fonc-10-606928-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8774/7894207/9fbb571d7a44/fonc-10-606928-g007.jpg

相似文献

1
Autophagy Gene Panel-Based Prognostic Model in Myelodysplastic Syndrome.基于自噬基因面板的骨髓增生异常综合征预后模型
Front Oncol. 2021 Feb 5;10:606928. doi: 10.3389/fonc.2020.606928. eCollection 2020.
2
Development of prognostic index based on autophagy-related genes analysis in breast cancer.基于自噬相关基因分析的乳腺癌预后指标的建立。
Aging (Albany NY). 2020 Jan 22;12(2):1366-1376. doi: 10.18632/aging.102687.
3
Development and validation of a survival model based on autophagy-associated genes for predicting prognosis of hepatocellular carcinoma.基于自噬相关基因的生存模型用于预测肝细胞癌预后的开发与验证
Am J Transl Res. 2020 Oct 15;12(10):6705-6722. eCollection 2020.
4
A predicted risk score based on the expression of 16 autophagy-related genes for multiple myeloma survival.基于16个自噬相关基因表达的多发性骨髓瘤生存预测风险评分。
Oncol Lett. 2019 Nov;18(5):5310-5324. doi: 10.3892/ol.2019.10881. Epub 2019 Sep 19.
5
Comparison of Stage 4 and Stage 4s Neuroblastoma Identifies Autophagy-Related Gene and LncRNA Signatures Associated With Prognosis.4期与4s期神经母细胞瘤的比较确定了与预后相关的自噬相关基因和长链非编码RNA特征。
Front Oncol. 2020 Aug 19;10:1411. doi: 10.3389/fonc.2020.01411. eCollection 2020.
6
Identification of an Autophagy-Related Prognostic Signature for Clear Cell Renal Cell Carcinoma.肾透明细胞癌自噬相关预后标志物的鉴定
Front Oncol. 2020 May 29;10:873. doi: 10.3389/fonc.2020.00873. eCollection 2020.
7
Construction and Validation of an Autophagy-Related Prognostic Risk Signature for Survival Predicting in Clear Cell Renal Cell Carcinoma Patients.用于预测透明细胞肾细胞癌患者生存的自噬相关预后风险特征的构建与验证
Front Oncol. 2020 May 5;10:707. doi: 10.3389/fonc.2020.00707. eCollection 2020.
8
A novel autophagy-related genes prognostic risk model and validation of autophagy-related oncogene VPS35 in breast cancer.一种新型自噬相关基因预后风险模型及自噬相关癌基因VPS35在乳腺癌中的验证
Cancer Cell Int. 2021 May 17;21(1):265. doi: 10.1186/s12935-021-01970-4.
9
Mutation status and burden can improve prognostic prediction of patients with lower-risk myelodysplastic syndromes.基因突变状态和负担可改善低危骨髓增生异常综合征患者的预后预测。
Cancer Sci. 2020 Feb;111(2):580-591. doi: 10.1111/cas.14270. Epub 2019 Dec 24.
10
Improved risk stratification by the integration of the revised international prognostic scoring system with the myelodysplastic syndromes comorbidity index.改良的国际预后评分系统与骨髓增生异常综合征合并症指数的整合提高了风险分层。
Eur J Cancer. 2014 Dec;50(18):3198-205. doi: 10.1016/j.ejca.2014.09.016. Epub 2014 Oct 28.

引用本文的文献

1
Restoration of Autophagy and Apoptosis in Myelodysplastic Syndromes: The Effect of Azacitidine in Disease Pathogenesis.骨髓增生异常综合征中自噬和凋亡的恢复:阿扎胞苷在疾病发病机制中的作用
Curr Issues Mol Biol. 2025 Jul 4;47(7):520. doi: 10.3390/cimb47070520.
2
Immunologic Predictors for Clinical Responses during Immune Checkpoint Blockade in Patients with Myelodysplastic Syndromes.免疫检查点阻断治疗骨髓增生异常综合征患者的临床反应的免疫预测因子。
Clin Cancer Res. 2023 May 15;29(10):1938-1951. doi: 10.1158/1078-0432.CCR-22-2601.
3
Development and validation of a novel prognosis prediction model for patients with myelodysplastic syndrome.

本文引用的文献

1
Common and different alterations of bone marrow mesenchymal stromal cells in myelodysplastic syndrome and multiple myeloma.骨髓间充质基质细胞在骨髓增生异常综合征和多发性骨髓瘤中的常见和不同改变。
Cell Prolif. 2020 May;53(5):e12819. doi: 10.1111/cpr.12819. Epub 2020 May 5.
2
Identification of a metabolic gene panel to predict the prognosis of myelodysplastic syndrome.鉴定一个代谢基因谱,以预测骨髓增生异常综合征的预后。
J Cell Mol Med. 2020 Jun;24(11):6373-6384. doi: 10.1111/jcmm.15283. Epub 2020 Apr 26.
3
Adaptive response to inflammation contributes to sustained myelopoiesis and confers a competitive advantage in myelodysplastic syndrome HSCs.
骨髓增生异常综合征患者新型预后预测模型的开发与验证
Front Oncol. 2022 Oct 12;12:1014504. doi: 10.3389/fonc.2022.1014504. eCollection 2022.
炎症的适应性反应有助于持续的髓系造血,并赋予骨髓增生异常综合征造血干细胞竞争优势。
Nat Immunol. 2020 May;21(5):535-545. doi: 10.1038/s41590-020-0663-z. Epub 2020 Apr 20.
4
Therapeutic strategies in low and high-risk MDS: What does the future have to offer?低危和高危 MDS 的治疗策略:未来有哪些选择?
Blood Rev. 2021 Jan;45:100689. doi: 10.1016/j.blre.2020.100689. Epub 2020 Mar 31.
5
Genetic basis of myelodysplastic syndromes.骨髓增生异常综合征的遗传学基础。
Proc Jpn Acad Ser B Phys Biol Sci. 2020;96(3):107-121. doi: 10.2183/pjab.96.009.
6
Myelodysplastic Syndromes: How to Recognize Risk and Avoid Acute Myeloid Leukemia Transformation.骨髓增生异常综合征:如何识别风险并避免急性髓系白血病转化。
Curr Oncol Rep. 2020 Jan 23;22(1):4. doi: 10.1007/s11912-020-0869-0.
7
Does mutational burden add to other prognostic factors in MDS?基因突变负担是否能为 MDS 的其他预后因素提供补充?
Best Pract Res Clin Haematol. 2019 Dec;32(4):101098. doi: 10.1016/j.beha.2019.101098. Epub 2019 Oct 18.
8
Genetic abnormalities and pathophysiology of MDS.骨髓增生异常综合征的遗传异常和病理生理学。
Int J Clin Oncol. 2019 Aug;24(8):885-892. doi: 10.1007/s10147-019-01462-6. Epub 2019 May 15.
9
Azacitidine resistance caused by LAMP2 deficiency: a therapeutic window for the use of autophagy inhibitors in MDS/AML patients?LAMP2 缺乏导致阿扎胞苷耐药:MDS/AML 患者使用自噬抑制剂的治疗窗口?
Autophagy. 2019 May;15(5):927-929. doi: 10.1080/15548627.2019.1586259. Epub 2019 Mar 1.
10
Genetics of MDS.骨髓增生异常综合征的遗传学。
Blood. 2019 Mar 7;133(10):1049-1059. doi: 10.1182/blood-2018-10-844621. Epub 2019 Jan 22.